Business Context and Reporting Period
Company: Arvinas, Inc.
Filing Type: Form 8-K (Current Report)
Date: February 17, 2022
Subject: Announcement of completed Phase 1 dose escalation data and interim Phase 2 ARDENT dose expansion data for bavdegalutamide (ARV-110), a PROTAC protein degrader for metastatic castration-resistant prostate cancer (mCRPC). Data cut-off date was December 20, 2021.
Key Financial Metrics
This filing is a current report regarding clinical trial results and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Results
The filing details significant clinical efficacy data for bavdegalutamide across 195 enrolled patients (71 in Phase 1, 124 in Phase 2). Key efficacy findings include:
- AR T878X/H875Y Mutations: In 28 biomarker-evaluable patients with these mutations, the PSA50 response rate was 46% and PSA30 was 57%. Two patients achieved confirmed durable partial responses.
- Wild-Type/Other Alterations: In 44 patients with wild-type AR or other alterations, PSA50 was 11% and PSA30 was 20%.
- AR L702H/AR-V7 Variants: In 25 patients with these variants, PSA50 was 4% and PSA30 was 20%.
- Less Pretreated Subgroup: In 27 patients with no more than one prior novel hormonal agent and no prior chemotherapy, PSA50 was 22% and PSA30 was 26%.
Safety Profile: At the recommended Phase 2 dose (420 mg once-daily), the drug showed a manageable tolerability profile. No Grade 4 or higher treatment-related adverse events (TRAEs) were observed in 138 patients. Common TRAEs included nausea (47% total), fatigue (36% total), and vomiting (26% total). Dose reductions occurred in 8% of patients, and discontinuations in 9%.
Guidance, Outlook, and Risks
Management Outlook:
- H1 2022: Initiate discussions with the FDA regarding an accelerated approval pathway for molecularly defined mCRPC and finalize a companion diagnostic partnership.
- H2 2022: Initiate a pivotal trial for patients with AR T878/H875 tumor mutations.
- Future Studies: Plan studies to explore treatment in earlier-line patients with AR-dependent tumors.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Risks include the uncertainty of clinical trial outcomes, regulatory approval timelines, and the ability to successfully commercialize product candidates. Actual results may differ materially from expectations.
Investor Verification Checklist
- Verify the specific definitions of the biomarker subgroups (T878X, H875Y, L702H, AR-V7) and their prevalence in the broader mCRPC population.
- Confirm the timeline for the FDA accelerated approval discussions and the companion diagnostic partnership.
- Review the full safety data for long-term treatment effects, as the current data cut-off is December 20, 2021.
- Monitor the initiation date of the pivotal trial planned for the second half of 2022.
- Check subsequent filings for updates on the company's cash position and burn rate, as this 8-K does not contain financial data.